FAM219B

Across TCGA pan-cancer cohorts, FAM219B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM219B data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM219B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FAM219B expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC and LSCC are the cancer types where FAM219B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.256	0.835	.006	14	view →
LSCC	DFS	Median	All	0.969	0.894	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FAM219B–PDAC (OS)

Open the PDAC breakdown →